Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Boundless Bio, Inc. Common Stock (BOLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BOLD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.09% | Avg. Invested days 5 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.19M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 1.00 - 4.72 | Updated Date 08/25/2025 |
52 Weeks Range 1.00 - 4.72 | Updated Date 08/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.27% | Return on Equity (TTM) -42.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -51446836 | Price to Sales(TTM) - |
Enterprise Value -51446836 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 22385600 | Shares Floating 16461961 |
Shares Outstanding 22385600 | Shares Floating 16461961 | ||
Percent Insiders 11.39 | Percent Institutions 55.83 |
Upturn AI SWOT
Boundless Bio, Inc. Common Stock
Company Overview
History and Background
Boundless Bio, Inc. is a clinical-stage oncology company dedicated to revolutionizing cancer treatment through the inhibition of extrachromosomal DNA (ecDNA) in aggressive cancers. Founded in 2018, the company is rapidly advancing a pipeline of novel therapeutics targeting this previously undruggable area of cancer biology.
Core Business Areas
- Oncology Drug Development: Focuses on discovering and developing innovative therapies targeting ecDNA biology in cancer. Primary focus is on treatments for genetically amplified cancers that do not respond to standard treatments.
Leadership and Structure
Carlos Garcia-Echeverria, PhD serves as the CEO, leading a team focused on scientific innovation and clinical development. The company has a structured organizational setup with specialized teams for research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- BBI-398: A first-in-class oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for the treatment of cancers with oncogene amplification. Currently in Phase 1/2 clinical trials. There is currently no market share and no revenue. Competitors: Other pharmaceutical companies developing DHODH inhibitors, though none specifically targeting ecDNA.
Market Dynamics
Industry Overview
The oncology drug development market is highly competitive and rapidly evolving, with increasing focus on personalized medicine and targeted therapies. The market is driven by the high prevalence of cancer and unmet needs for effective treatments, especially in areas like genetically amplified cancers.
Positioning
Boundless Bio is positioned as a pioneer in the field of ecDNA-directed cancer therapy, aiming to address a significant unmet need in treating genetically amplified cancers. Its competitive advantage lies in its novel approach and proprietary platform for identifying and targeting ecDNA.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars annually. The specific TAM for ecDNA-driven cancers is still being defined but represents a substantial portion of genetically amplified cancers. Boundless Bio is aiming to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting ecDNA
- Strong scientific foundation and intellectual property
- Experienced leadership team
- First-in-class DHODH inhibitor in clinical development
Weaknesses
- Early-stage clinical development (high risk)
- Reliance on a single therapeutic area (ecDNA)
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Potential for breakthrough therapies in genetically amplified cancers
- Partnerships with larger pharmaceutical companies
- Expansion into new indications beyond initial targets
- Positive clinical trial data driving market adoption
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- SNY
- MRK
- BMY
Competitive Landscape
Boundless Bio competes with established pharmaceutical companies in the broader oncology market, but its ecDNA-targeted approach provides a unique competitive advantage. However, it faces the challenges of clinical development and commercialization in a highly competitive environment.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data available due to the company's recent founding and IPO.
Future Projections: Future growth is dependent on the success of its clinical trials and regulatory approvals. Analyst estimates vary widely based on the potential of its ecDNA-targeted therapies.
Recent Initiatives: Advancing BBI-398 through Phase 1/2 clinical trials; expanding research efforts to identify new ecDNA targets.
Summary
Boundless Bio is a high-risk, high-reward clinical-stage oncology company pioneering therapies targeting ecDNA. Its innovative approach offers significant potential in treating genetically amplified cancers. Success hinges on positive clinical trial results, funding and regulatory approvals. Investors should note that they face heavy competition from larger firms in the marketplace.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Boundless Bio Corporate Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Investing in biotechnology companies carries significant risks, including clinical trial failures and regulatory hurdles.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boundless Bio, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-03-28 | CEO, President & Director Mr. Zachary Hornby | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://boundlessbio.com |
Full time employees 64 | Website https://boundlessbio.com | ||
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.